iTeos Therapeutics (NASDAQ:ITOS) Shares Down 4.5%

iTeos Therapeutics, Inc. (NASDAQ:ITOS) traded down 4.5% during trading on Monday . The stock traded as low as $15.43 and last traded at $15.50. 149,203 shares changed hands during trading, a decline of 56% from the average session volume of 342,707 shares. The stock had previously closed at $16.23.

Wall Street Analyst Weigh In

ITOS has been the topic of several research reports. HC Wainwright lifted their price target on shares of iTeos Therapeutics from $44.00 to $46.00 and gave the company a “buy” rating in a report on Monday, May 13th. Wedbush reiterated an “outperform” rating and set a $18.00 price target (down from $25.00) on shares of iTeos Therapeutics in a report on Wednesday, March 6th.

iTeos Therapeutics Stock Down 6.2 %

The stock’s 50-day simple moving average is $14.43 and its 200 day simple moving average is $12.16. The firm has a market cap of $550.11 million, a P/E ratio of -4.07 and a beta of 1.42.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Friday, May 10th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.05). On average, research analysts forecast that iTeos Therapeutics, Inc. will post -4.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On iTeos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ITOS. PNC Financial Services Group Inc. raised its holdings in shares of iTeos Therapeutics by 131.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,287 shares of the company’s stock worth $25,000 after acquiring an additional 1,299 shares during the last quarter. Federated Hermes Inc. increased its position in shares of iTeos Therapeutics by 4,648.4% during the fourth quarter. Federated Hermes Inc. now owns 2,944 shares of the company’s stock valued at $32,000 after acquiring an additional 2,882 shares during the last quarter. Gladius Capital Management LP increased its position in shares of iTeos Therapeutics by 48.7% during the 4th quarter. Gladius Capital Management LP now owns 3,131 shares of the company’s stock valued at $34,000 after purchasing an additional 1,026 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in iTeos Therapeutics by 348.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,140 shares of the company’s stock worth $45,000 after acquiring an additional 3,216 shares during the period. Finally, Signaturefd LLC raised its holdings in shares of iTeos Therapeutics by 268.5% in the 4th quarter. Signaturefd LLC now owns 4,481 shares of the company’s stock worth $49,000 after purchasing an additional 3,265 shares during the period. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.